DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

To join this study, you need to be an adult (18 years or older) with DLBCL that has either returned or not responded to at least two previous treatments. One of these past treatments must have included certain common lymphoma medicines like an anthracycline and rituximab. You also need to be well enough to take part, meaning you can carry out most of your daily activities without much difficulty.

You would not be able to join if you have cancer that has spread to your brain or spinal cord, or if you've had major surgery, chemotherapy, or radiotherapy very recently. Also, if you've had certain other treatments like a stem cell transplant or CAR-T cell therapy within a specific recent time frame, you wouldn't be eligible. The study also cannot include you if you have certain other serious medical conditions, such as some autoimmune diseases or uncontrolled infections.

Doctors will carefully review your full medical history and current health to see if the study is a safe and suitable option for you. They will look at your blood test results and other scans to make sure you meet all the safety requirements for the treatment.

If you decide to take part in this study, you will be randomly assigned to one of two treatment groups, like flipping a coin. You will receive doses of DPX-Survivac and pembrolizumab. If you are in one of the groups, you will also receive low-dose cyclophosphamide.

DPX-Survivac will be given as injections. You'll get two injections three weeks apart at the start, followed by smaller doses every eight weeks. Pembrolizumab will be given through a drip into your vein (IV) every three weeks. If you are in the group receiving cyclophosphamide, you'll take it as a tablet twice a day for 7 days, then have 7 days off, and this cycle will repeat throughout the study.

Throughout the study, you will have regular visits to the clinic for medical check-ups, blood tests, and scans to see how you are responding to the treatment and to monitor for any side effects. You will also need to provide tissue samples from your tumour, both at the start and during the treatment. The total duration of your active treatment in the study and subsequent follow-up will be explained by your study doctor.